JPWO2020122093A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020122093A5 JPWO2020122093A5 JP2020559268A JP2020559268A JPWO2020122093A5 JP WO2020122093 A5 JPWO2020122093 A5 JP WO2020122093A5 JP 2020559268 A JP2020559268 A JP 2020559268A JP 2020559268 A JP2020559268 A JP 2020559268A JP WO2020122093 A5 JPWO2020122093 A5 JP WO2020122093A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- optionally substituted
- ring
- alkyl
- groups
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 13
- 125000005843 halogen group Chemical group 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 125000001424 substituent group Chemical group 0.000 claims 9
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims 5
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims 3
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 3
- -1 formylcarbonyl group Chemical group 0.000 claims 3
- 201000003631 narcolepsy Diseases 0.000 claims 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 1
- QPDFCVIMRQHVFW-UHFFFAOYSA-N N-[2-ethyl-7-[[1-(5-fluoropyrimidin-2-yl)piperidin-4-yl]oxymethyl]-4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-6-yl]methanesulfonamide Chemical compound C(C)C1=NN2C(CCC(C2COC2CCN(CC2)C2=NC=C(C=N2)F)NS(=O)(=O)C)=C1 QPDFCVIMRQHVFW-UHFFFAOYSA-N 0.000 claims 1
- SUTARHSQDHRJKK-UHFFFAOYSA-N N-[2-propan-2-yl-7-[(1-pyrimidin-2-ylpiperidin-4-yl)oxymethyl]-4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-6-yl]methanesulfonamide Chemical compound CC(C)C1=NN2C(CCC(C2COC2CCN(CC2)C2=NC=CC=N2)NS(=O)(=O)C)=C1 SUTARHSQDHRJKK-UHFFFAOYSA-N 0.000 claims 1
- LQXDOQOAYTVLIZ-UHFFFAOYSA-N N-[7-[[1-(5-fluoropyrimidin-2-yl)piperidin-4-yl]oxymethyl]-2-propan-2-yl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-6-yl]methanesulfonamide Chemical compound FC=1C=NC(=NC1)N1CCC(CC1)OCC1C(CCC=2N1N=C(C2)C(C)C)NS(=O)(=O)C LQXDOQOAYTVLIZ-UHFFFAOYSA-N 0.000 claims 1
- 102000002512 Orexin Human genes 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 108060005714 orexin Proteins 0.000 claims 1
- 125000003431 oxalo group Chemical group 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018232993 | 2018-12-12 | ||
| JP2018232993 | 2018-12-12 | ||
| PCT/JP2019/048385 WO2020122093A1 (ja) | 2018-12-12 | 2019-12-11 | 複素環化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2020122093A1 JPWO2020122093A1 (ja) | 2021-10-21 |
| JPWO2020122093A5 true JPWO2020122093A5 (https=) | 2022-12-19 |
| JP7408569B2 JP7408569B2 (ja) | 2024-01-05 |
Family
ID=71077291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020559268A Active JP7408569B2 (ja) | 2018-12-12 | 2019-12-11 | 複素環化合物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US12091410B2 (https=) |
| EP (1) | EP3896060B1 (https=) |
| JP (1) | JP7408569B2 (https=) |
| WO (1) | WO2020122093A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7379374B2 (ja) | 2018-12-12 | 2023-11-14 | 武田薬品工業株式会社 | 複素環化合物 |
| EP3896060B1 (en) | 2018-12-12 | 2023-08-16 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| SG11202106791XA (en) | 2019-01-31 | 2021-07-29 | Takeda Pharmaceuticals Co | Heterocyclic compound and use thereof |
| FI4065585T3 (fi) | 2019-11-25 | 2025-09-26 | Alkermes Inc | Substituoituja makrosyklisiä yhdisteitä ja niihin liittyviä hoitomenetelmiä |
| WO2021106975A1 (ja) | 2019-11-27 | 2021-06-03 | 武田薬品工業株式会社 | 複素環化合物 |
| BR112023002957A2 (pt) | 2020-08-18 | 2023-04-04 | Merck Sharp & Dohme Llc | Composto, composição farmacêutica, e, métodos para tratar narcolepsia e para tratar hipersonia em um sujeito mamífero |
| US12503475B2 (en) | 2020-09-03 | 2025-12-23 | Centessa Pharmaceuticals (Uk) Limited | Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| US12006330B2 (en) | 2020-12-21 | 2024-06-11 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
| BR112023020104A2 (pt) | 2021-04-02 | 2023-11-14 | Takeda Pharmaceuticals Co | Métodos para recuperação pós-operação, para facilitar a recuperação ou reduzir o tempo de recuperação da anestesia, para prevenir ou tratar distúrbios/depressão respiratória pós-operatória ou distúrbios/depressão respiratória induzida por opioides, sedação pós-operatória ou sedação induzida por opioides e para reduzir um efeito colateral de opioides |
| JP7591592B2 (ja) * | 2022-01-14 | 2024-11-28 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 置換ピペリジン化合物を含有する医薬 |
| CN118451076A (zh) * | 2022-01-14 | 2024-08-06 | 卫材R&D管理有限公司 | 经取代的哌啶化合物的晶体、经取代的哌啶化合物的盐及其晶体 |
| EP4508027A1 (en) | 2022-04-12 | 2025-02-19 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| AR130906A1 (es) | 2022-10-31 | 2025-01-29 | Takeda Pharmaceuticals Co | Compuesto heterocíclico que tiene actividad agonista del receptor de orexina tipo 2 |
| TW202440562A (zh) | 2022-11-30 | 2024-10-16 | 日商武田藥品工業股份有限公司 | 雜環化合物及其用途 |
| KR20250155550A (ko) | 2023-03-16 | 2025-10-30 | 다케다 야쿠힌 고교 가부시키가이샤 | 매크로시클릭 헤테로시클 화합물 및 이의 용도 |
| WO2025124698A1 (en) | 2023-12-12 | 2025-06-19 | Idorsia Pharmaceuticals Ltd | Aryl sulfone and sulfanone derivatives as orexin receptor modulators |
| TW202542165A (zh) | 2023-12-19 | 2025-11-01 | 瑞士商愛杜西亞製藥有限公司 | 大環食慾素激動劑 |
| WO2025224168A1 (en) | 2024-04-24 | 2025-10-30 | Idorsia Pharmaceuticals Ltd | Aryl sulfone and sulfanone derivatives as orexin receptor modulators |
| WO2025229494A1 (en) | 2024-04-29 | 2025-11-06 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2025229495A1 (en) | 2024-04-29 | 2025-11-06 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6166193A (en) | 1997-07-25 | 2000-12-26 | Board Of Regents, University Of Texas System | Polynucleotides encoding MY1 receptor |
| CA2374610A1 (en) | 1999-06-28 | 2001-01-04 | Jordan J. N. Tang | Catalytically active recombinant memapsin and methods of use thereof |
| WO2001008720A2 (en) | 1999-07-30 | 2001-02-08 | The Board Of Trustees Of The Leland Stanford Junior University | Hypocretin and hypocretin receptors in regulation of sleep and related disorders |
| WO2001074162A1 (en) | 2000-04-04 | 2001-10-11 | The Regents Of The University Of California | Treatment of sleep disorders with hypocretin-1 |
| EP1581648A2 (en) | 2002-09-09 | 2005-10-05 | Nura, Inc. | G protein coupled receptors and uses thereof |
| JP2006518709A (ja) | 2002-12-13 | 2006-08-17 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒトオレキシン−２受容体のモジュレーターを同定する方法 |
| WO2009049215A1 (en) | 2007-10-10 | 2009-04-16 | Wake Forest University Health Sciences | Methods to reduce the effects of sleep deprivation |
| US8258163B2 (en) | 2008-06-04 | 2012-09-04 | Board Of Regents, The University Of Texas System | Small-molecule agonists for type-2 orexin receptor |
| EP2510104A2 (en) | 2009-11-02 | 2012-10-17 | Basf Se | Process for producing polyamines comprising the enzymatic oxidation of amino alcohols |
| EP2694472B1 (en) | 2011-04-05 | 2020-03-11 | Takeda Pharmaceutical Company Limited | Sulfonamide derivative and use thereof |
| WO2014170343A1 (en) | 2013-04-15 | 2014-10-23 | Icm (Institut Du Cerveau Et De La Moelle Épinière) | Depolarizing agents and nicotinic acetylcholine receptor modulators for treating dopaminergic-related disorders |
| WO2014198880A1 (en) | 2013-06-14 | 2014-12-18 | Ferrer Internacional, S.A. | 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity |
| ITBO20130077U1 (it) | 2013-07-04 | 2015-01-05 | Cefla Coop | Piano a spessore ribassato per scaffalature metalliche per l'esposizione delle merci |
| US20160250224A1 (en) | 2013-09-24 | 2016-09-01 | The Board Of Regents Of The University Of Texas System | Orexin-control of bone formation and loss |
| CA2930693A1 (en) | 2013-11-15 | 2015-05-21 | The Board Of Trustees Of The Leland Stanford Junior Unversity | Methods of treating heart failure with agonists of hypocretin receptor 2 |
| WO2015147240A1 (ja) | 2014-03-28 | 2015-10-01 | 国立大学法人筑波大学 | 敗血症の予防治療剤 |
| UY36272A (es) | 2014-08-13 | 2016-02-29 | Eolas Therapeutics Inc | Difluoropirrolidinas como moduladores de los receptores de orexinas |
| EP3029024A1 (en) | 2014-12-02 | 2016-06-08 | Ferrer Internacional, S.A. | 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity |
| WO2016199906A1 (ja) | 2015-06-12 | 2016-12-15 | 国立大学法人筑波大学 | スルホンアミド誘導体またはその薬学的に許容される酸付加塩 |
| PL3411358T3 (pl) * | 2016-02-04 | 2022-02-28 | Takeda Pharmaceutical Company Limited | Podstawiony związek piperydynowy i jego zastosowanie |
| WO2018164191A1 (ja) | 2017-03-08 | 2018-09-13 | 武田薬品工業株式会社 | 置換ピロリジン化合物およびその用途 |
| US11034700B2 (en) | 2017-03-08 | 2021-06-15 | Takeda Pharmaceutical Company Limited | Substituted pyrrolidine compound and use thereof |
| US20200207734A1 (en) | 2017-08-03 | 2020-07-02 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| US11319286B2 (en) | 2017-08-03 | 2022-05-03 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
| WO2019112007A1 (ja) | 2017-12-07 | 2019-06-13 | 国立大学法人 筑波大学 | 鎮痛薬による眠気の予防または治療薬 |
| US12077522B2 (en) * | 2018-06-29 | 2024-09-03 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
| JP7413261B2 (ja) * | 2018-06-29 | 2024-01-15 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| EP3896060B1 (en) | 2018-12-12 | 2023-08-16 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2020167701A1 (en) | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | Pyrrolidine orexin receptor agonists |
| US11098029B2 (en) | 2019-02-13 | 2021-08-24 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
-
2019
- 2019-12-11 EP EP19895161.8A patent/EP3896060B1/en active Active
- 2019-12-11 WO PCT/JP2019/048385 patent/WO2020122093A1/ja not_active Ceased
- 2019-12-11 JP JP2020559268A patent/JP7408569B2/ja active Active
- 2019-12-11 US US17/413,473 patent/US12091410B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020122093A5 (https=) | ||
| JP7037679B2 (ja) | 新規の二環式ブロモドメイン阻害剤 | |
| AU2013361127B2 (en) | Compounds and methods for kinase modulation, and indications therefor | |
| AU2016256728B2 (en) | Thiadiazole analogs thereof and methods for treating smn-deficiency-related-conditions | |
| CA2451678C (en) | Azaindoles | |
| US9550796B2 (en) | Pyrrolopyrrolone derivatives and their use as BET inhibitors | |
| JP2013523884A5 (https=) | ||
| JP2019536785A5 (https=) | ||
| NO343370B1 (no) | Bisykliske heterosykliske forbindelser som FGFR-inhibitorer, farmasøytisk sammensetning og terapeutisk anvendelse | |
| WO2014191894A1 (en) | Imidazopyrrolidinone derivatives and their use in the treatment of disease | |
| JP2009522346A (ja) | Ｐｄｅ１０阻害剤としての二環式ヘテロアリール化合物 | |
| RU2017125025A (ru) | Конденсированные кольцевые гетероарильные соединения и их применение в качестве ингибиторов trk | |
| WO2011084486A1 (en) | 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof | |
| JPWO2005085214A1 (ja) | ジアリール置換複素５員環誘導体 | |
| TW200412950A (en) | Thieno [3, 2-b] pyridine-6-carbonitriles and thieno [2, 3-b] pyridine-5-carbonitriles as protein kinase inhibitors | |
| CA2670362A1 (en) | Compounds modulating c-fms and/or c-kit activity and uses therefor | |
| JP2009521492A (ja) | オーロラキナーゼのアザインドール阻害薬 | |
| TW201247673A (en) | Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders | |
| HRP20020547A2 (hr) | Azaindoles | |
| KR20120124469A (ko) | 헤트아릴-［1,8］나프티리딘 유도체 | |
| CN109843883A (zh) | 作为选择性jak抑制剂化合物，该化合物的盐类及其治疗用途 | |
| WO2014079364A1 (zh) | 咪唑酮类衍生物、其药物组合物和用途 | |
| CN118974036A (zh) | Raf激酶的抑制剂 | |
| AU2008273050A2 (en) | Pyrazolo[1,5-a]pyridines and their use in cancer therapy | |
| JP2016517877A5 (https=) |